Antitope, PolyTherics deal
PolyTherics merged with Antitope, which will operate as a wholly owned PolyTherics subsidiary. PolyTherics said the subsidiary will provide immunogenicity testing, antibody humanization and protein re-engineering technologies, including Antitope's EpiScreen, Composite Human Antibody and Composite Protein. EpiScreen is an ex vivo human T cell assay technology used for predicting the immunogenicity of biologics or for identifying T cell epitopes within the sequences of biologics. Composite Human Antibody generates humanized antibodies devoid of human T cell epitopes and Composite Protein generates therapeutic proteins devoid of human T cell epitopes. PolyTherics provides technology solutions to develop better biopharmaceuticals and offers site-specific conjugation technologies and polymers to optimize therapeutic properties of biopharmaceuticals. PolyTherics declined to disclose details. ...